Patents by Inventor Jianglan LONG

Jianglan LONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12029747
    Abstract: A use of baicalin in preparation of a drug for treating a tumor irresponsive to immune checkpoint inhibitors (ICIs)/undergoing hyperprogression is provided, where the non-response to ICIs/hyperprogression of the tumor is caused by excessive Foxp3+Treg cells; the targeted tumor is one selected from the group consisting of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer; and the ICIs is one or a mixture of two or more selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. In the present disclosure, baicalin is used in combination with ICIs to inhibit a number of Foxp3+Treg cells in a tumor to play an anti-tumor sensitization effect, which can effectively treat a variety of tumors irresponsive to ICIs/undergoing hyperprogression caused by excessive Foxp3+Treg cells.
    Type: Grant
    Filed: September 28, 2023
    Date of Patent: July 9, 2024
    Assignee: BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITY
    Inventors: Dan Yan, Yu Zhang, Wei Zhao, Bangwei Cao, Aiting Wang, Jianglan Long
  • Publication number: 20240180943
    Abstract: A use of baicalin in preparation of a drug for treating a tumor irresponsive to immune checkpoint inhibitors (ICIs)/undergoing hyperprogression is provided, where the non-response to ICIs/hyperprogression of the tumor is caused by excessive Foxp3+Treg cells; the targeted tumor is one selected from the group consisting of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer, and the ICIs is one or a mixture of two or more selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. In the present disclosure, baicalin is used in combination with ICIs to inhibit a number of Foxp3+Treg cells in a tumor to play an anti-tumor sensitization effect, which can effectively treat a variety of tumors irresponsive to ICIs/undergoing hyperprogression caused by excessive Foxp3+Treg cells.
    Type: Application
    Filed: September 28, 2023
    Publication date: June 6, 2024
    Applicant: BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITY
    Inventors: Dan YAN, Yu ZHANG, Wei ZHAO, Bangwei CAO, Aiting WANG, Jianglan LONG
  • Publication number: 20230282355
    Abstract: An integrated biomarker system for evaluating a risk of impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM) for the first time is disclosed. The integrated biomarker system includes quantitative determination results of L-glutamine, L-valine, L-leucine, L-lysine, L-proline, L-phenylalanine, L-arginine, L-glutamic acid, L-isoleucine, L-methionine, L-carnitine, acetyl-L-carnitine, lysophosphatidyl choline (LPC (P-16:0)), LPC (17:0), LPC (14:0) and propionyl-L-carnitine in a sample. The integrated biomarker system for IFG and T2DM of subject serum sample contains a correlative biomarker group on a biological network path to reflect the overall metabolic characteristics information of IFG and T2DM and to avoid that characteristic information of a disease cannot be reflected integrally and completely due to single or separate analysis of a biomarker.
    Type: Application
    Filed: April 26, 2021
    Publication date: September 7, 2023
    Applicant: BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITY
    Inventors: Dan YAN, Jianglan LONG, Zhirui YANG